Cara Therapeutics Inc. (CARA)

19.04 +0.28 (+1.493%)

IEX Real-Time Price

November 16, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 18.76

Price Open 18.75

Volume: 413,491

Avg Volume: 548,596

Market Cap: 751.07M

P/E Ratio -9.66

52 Wk Range 11.46-24.3



CARA Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
37.78M
6.25M
7.49
16.54%

2018-09-28
37.76M
5.53M
6.94
14.63%

2018-09-14
37.76M
5.19M
8.76
13.75%

2018-08-31
37.76M
5.25M
8.15
13.91%




CARA Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-11-06
Q3 2018
AMC
-0.46 (5)
-0.51
-0.05

2018-08-07
Q2 2018
AMC
-0.50 (5)
-0.52
-0.02

2018-05-09
Q1 2018
AMC
-0.47 (5)
-0.51
-0.04

2018-05-03
Q1 2018
N/A
-0.40 (4)
0.00
0.00

News

Cara Therapeutics Inc. (CARA) CEO Derek Chalmers on Q3 2018 Results - Earnings Call Transcript (2018-11-06 22:47 SeekingAlpha)

Cara Therapeutics Inc. (CARA) Q3 2018 Results Earnings Conference Call November 06, 2018, 04:30 PM ET Executives Michael Schaffzin - Stern Investor Relations Derek Chalmers - Co-Founder, President, CEO & Director Mani Mohindru - CFO & Chief Strategy Officer Analysts …

 


Statistics

Shares Outstanding: 39.45M

Top 15 Institution Percent: 47.00

Price To Sales: 93.25

Price To Book: 4.95

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -42.11

Return On Equity: -54.33

Profit Margin: N/A

Price History

Beta: 2.95

50-day Moving Avg: 20.48

200-day Moving Avg: 16.79

YTD Change: 48.29

5-day Change: 0.63

1-month Change: -3.94

3-month Change: -1.24

6-month Change: 47.25

1-year Change: 47.71

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Cara Therapeutics Inc.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.caratherapeutics.com

Cara Therapeutics Inc is an emerging biotechnology company. It is focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors.